These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 25105662)
21. A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study. Makówka A; Olejniczak-Fortak M; Nowicki M Kidney Blood Press Res; 2012; 36(1):18-25. PubMed ID: 22777192 [TBL] [Abstract][Full Text] [Related]
22. [Advantages and limitations of renin inhibition with aliskiren]. Azizi M; Frank M; Steichen O; Blanchard A Ann Pharm Fr; 2011 May; 69(3):142-50. PubMed ID: 21570538 [TBL] [Abstract][Full Text] [Related]
23. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906 [TBL] [Abstract][Full Text] [Related]
24. Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients? Gaddam KK; Oparil S Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):484-90. PubMed ID: 18695389 [TBL] [Abstract][Full Text] [Related]
25. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Desai AS; Nicolaides M; Richard A; Xiang Z; Brunel P; Pfeffer MA; N Engl J Med; 2012 Dec; 367(23):2204-13. PubMed ID: 23121378 [TBL] [Abstract][Full Text] [Related]
26. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP; JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743 [TBL] [Abstract][Full Text] [Related]
27. Direct renin inhibition--a promising strategy for renal protection? Lizakowski S; Tylicki L; Rutkowski B Med Sci Monit; 2013 Jun; 19():451-7. PubMed ID: 23756824 [TBL] [Abstract][Full Text] [Related]
28. Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease. Li SY; Chen YT; Yang WC; Tarng DC; Lin CC; Yang CY; Liu WS BMC Nephrol; 2012 Aug; 13():89. PubMed ID: 22917002 [TBL] [Abstract][Full Text] [Related]
29. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. Persson F; Lewis JB; Lewis EJ; Rossing P; Hollenberg NK; Hans-Henrik P J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):118-21. PubMed ID: 21824990 [TBL] [Abstract][Full Text] [Related]
30. Aliskiren: the first direct renin inhibitor available for clinical use. Morganti A; Lonati C J Nephrol; 2011; 24(5):541-9. PubMed ID: 21786226 [TBL] [Abstract][Full Text] [Related]
31. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Nicolaides M; Richard A; Xiang Z; Armbrecht J; Pfeffer MA; J Renin Angiotensin Aldosterone Syst; 2012 Sep; 13(3):387-93. PubMed ID: 22333485 [TBL] [Abstract][Full Text] [Related]
32. Aliskiren and losartan trial in non-diabetic chronic kidney disease. Woo KT; Choong HL; Wong KS; Tan HK; Foo M; Fook-Chong S; Lee EJ; Anantharaman V; Lee GS; Chan CM J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):515-22. PubMed ID: 24742970 [TBL] [Abstract][Full Text] [Related]
33. Aliskiren: an oral renin inhibitor for the treatment of hypertension. Lam S; Choy M Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068 [TBL] [Abstract][Full Text] [Related]
34. How are physicians prescribing the direct renin inhibitor aliskiren in the management of essential hypertension? A French observational study. Sosner P; Fiquet B; Quere S; Francillon A; Herpin D J Hypertens; 2013 Jul; 31(7):1491-6; discussion 1496. PubMed ID: 24006041 [TBL] [Abstract][Full Text] [Related]
35. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Pitt B; Latini R; Maggioni AP; Solomon SD; Smith BA; Wright M; Prescott MF; McMurray JJ Eur J Heart Fail; 2011 Jul; 13(7):755-64. PubMed ID: 21467028 [TBL] [Abstract][Full Text] [Related]
36. New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease. Feldman DL Hypertens Res; 2010 Apr; 33(4):279-87. PubMed ID: 20203685 [TBL] [Abstract][Full Text] [Related]
37. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study. Szeto CC; Kwan BC; Chow KM; Leung CB; Li PK PLoS One; 2013; 8(5):e62736. PubMed ID: 23675422 [TBL] [Abstract][Full Text] [Related]
38. Aliskiren in the treatment of hypertension and organ damage. Riccioni G Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033 [TBL] [Abstract][Full Text] [Related]
39. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). Schroten NF; Damman K; Hemmelder MH; Voors AA; Navis G; Gaillard CA; van Veldhuisen DJ; Van Gilst WH; Hillege HL Am Heart J; 2015 May; 169(5):693-701.e3. PubMed ID: 25965717 [TBL] [Abstract][Full Text] [Related]